Teva Pharmaceutical Industries Limited
TEVA
$15.71
$0.020.13%
NYSE
Recommendation
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
--
P/E (TTM)
--
EPS (TTM)
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 133.33% | 253.96% | -146.87% | -733.33% | 2.98% |
| Total Depreciation and Amortization | -3.09% | -10.29% | 1.13% | -8.48% | -13.67% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -95.71% | -42.92% | 371.17% | 561.67% | 2.34% |
| Change in Net Operating Assets | -3,260.00% | -40.85% | -183.90% | 239.65% | -104.72% |
| Cash from Operations | 120.39% | 15.32% | -51.44% | 13,760.00% | -68.21% |
| Capital Expenditure | 1.03% | -2.42% | -8.40% | 0.67% | 18.49% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | 800.00% | -- | -- | 280.00% | -98.21% |
| Other Investing Activities | 17.88% | 9.89% | -22.14% | 17.03% | -24.93% |
| Cash from Investing | 32.58% | 39.58% | -32.89% | 45.65% | -41.06% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -140.59% | -- | -37.00% | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 110.00% | -149.01% | 114.47% | -- | 81.82% |
| Cash from Financing | 100.62% | -1,054.97% | -17.01% | -- | -1,656.36% |
| Foreign Exchange rate Adjustments | 89.80% | 143.27% | -277.94% | 403.03% | 36.36% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 163.30% | -579.24% | -101.94% | 352.62% | -248.38% |